<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg"/></p>
<p>罗氏将负责抗体选择、连接、临床前和临床开发以及商业化。图片来源：Melnikov Dmitriy / Shutterstock.com。</p>
<p>罗氏与 C4 Therapeutics 签署了一项新的合作协议，旨在共同推进降解剂 - 抗体偶联物（DACs）领域的研究，目标是引入一种新的癌症治疗方式。</p>
<p>根据联合研究计划，两家公司将合作开发针对未披露的肿瘤靶点的两个 DAC 项目。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - 单克隆抗体偶联物 3 针对 Egfr...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - 单克隆抗体偶联物 3 针对 Egfr...</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>C4 Therapeutics 将利用其 TORPEDO 平台进行降解剂载荷设计，而罗氏将负责抗体选择、连接、临床前和临床开发以及商业化。</p>
<p>C4 Therapeutics 将获得 2000 万美元的预付款和额外的发现里程碑付款，潜在收益超过 10 亿美元的监管和商业里程碑，以及未来销售的分级版税。</p>
<p>C4 Therapeutics 总裁兼首席执行官 Andrew Hirsch 表示：“在过去十年中，C4T 与罗氏合作推动靶向蛋白降解的研究，并将这一方式确立为治疗癌症的新方法。</p>
<p>“我们的新合作利用了 C4T 设计高催化性和选择性降解剂的能力，以及 DACs 的降解剂载荷，同时结合了罗氏在开发具有特定结合能力的 ADC 方面的丰富经验。”</p>
<p>“这些能力共同构建了一种强大的新方式，可以为患者提供变革性的药物。”</p>
<p>罗氏企业业务发展负责人 Boris Zaïtra 表示：“罗氏早期就相信靶向蛋白降解及其潜在的差异化，在 2016 年首次与 C4T 合作时便已如此。</p>
<p>“我们与 C4 Therapeutics 的关系建立在十年的信任和共同的科学抱负之上。我们很高兴进入第三次合作，扩展我们长期的伙伴关系，以开创 DACs 这一新兴方式。”</p>
<p>2026 年 2 月，罗氏 获得了美国食品药品监督管理局的接受 其提交的 giredestrant 口服治疗的新药申请，以及与依维莫司联合治疗乳腺癌的申请。</p>

医疗业 ETF - SPDR

CCCC

纽交所高增长板生物技术指数 ETF - First Trust

<p>罗氏与 C4 Therapeutics 达成合作，以推进针对癌症治疗的降解剂 - 抗体偶联物（DACs）研究。罗氏将负责抗体的选择、开发和商业化，而 C4 Therapeutics 将利用其 TORPEDO 平台进行药物载体设计。该交易包括 2000 万美元的预付款，以及超过 10 亿美元的潜在里程碑和版税收入。这一合作建立在十年的合作基础上，旨在开创癌症治疗的新疗法</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-10-04-2026-shutterstock_2006854028-430x241.jpg"/></p>
<p>Roche will manage antibody selection, conjugation, preclinical and clinical development, and commercialisation. Credit: Melnikov Dmitriy / Shutterstock.com.</p>
<div class="lb-trans"><p>罗氏将负责抗体选择、连接、临床前和临床开发以及商业化。图片来源：Melnikov Dmitriy / Shutterstock.com。</p>
</div><p>Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.</p>
<div class="lb-trans"><p>罗氏与 C4 Therapeutics 签署了一项新的合作协议，旨在共同推进降解剂 - 抗体偶联物（DACs）领域的研究，目标是引入一种新的癌症治疗方式。</p>
</div><p>According to the joint research plan, the companies will partner on two programmes for developing DACs against undisclosed oncology targets.</p>
<div class="lb-trans"><p>根据联合研究计划，两家公司将合作开发针对未披露的肿瘤靶点的两个 DAC 项目。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 单克隆抗体偶联物 3 针对 Egfr...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Monoclonal Antibody Conjugate 3 To Target Egfr...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - 单克隆抗体偶联物 3 针对 Egfr...</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>C4 Therapeutics will use its TORPEDO platform for degrader payload design while Roche will manage antibody selection, conjugation, preclinical and clinical development, and commercialisation.</p>
<div class="lb-trans"><p>C4 Therapeutics 将利用其 TORPEDO 平台进行降解剂载荷设计，而罗氏将负责抗体选择、连接、临床前和临床开发以及商业化。</p>
</div><p>C4 Therapeutics will receive a $20m upfront payment and additional discovery milestone payments, with potential to earn more than $1bn in regulatory and commercial milestones, plus tiered royalties on future sales.</p>
<div class="lb-trans"><p>C4 Therapeutics 将获得 2000 万美元的预付款和额外的发现里程碑付款，潜在收益超过 10 亿美元的监管和商业里程碑，以及未来销售的分级版税。</p>
</div><p>C4 Therapeutics president and CEO Andrew Hirsch said: “For the past decade, C4T and Roche have worked together to drive research in targeted protein degradation and to establish this modality as a new way to treat cancer.</p>
<div class="lb-trans"><p>C4 Therapeutics 总裁兼首席执行官 Andrew Hirsch 表示：“在过去十年中，C4T 与罗氏合作推动靶向蛋白降解的研究，并将这一方式确立为治疗癌症的新方法。</p>
</div><p>“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding.”</p>
<div class="lb-trans"><p>“我们的新合作利用了 C4T 设计高催化性和选择性降解剂的能力，以及 DACs 的降解剂载荷，同时结合了罗氏在开发具有特定结合能力的 ADC 方面的丰富经验。”</p>
</div><p>“Together, these capabilities build a powerful new modality that can offer transformative medicines for patients.”</p>
<div class="lb-trans"><p>“这些能力共同构建了一种强大的新方式，可以为患者提供变革性的药物。”</p>
</div><p>Roche corporate business development head Boris Zaïtra said: “Roche has been a believer in targeted protein degradation and its potential for differentiation early on, when partnering with C4T for the first time in 2016.</p>
<div class="lb-trans"><p>罗氏企业业务发展负责人 Boris Zaïtra 表示：“罗氏早期就相信靶向蛋白降解及其潜在的差异化，在 2016 年首次与 C4T 合作时便已如此。</p>
</div><p>“Our relationship with C4 Therapeutics is built on a decade of trust and shared scientific ambition. We are pleased to enter into our third collaboration, expanding our long-standing partnership to pioneer the emerging modality of DACs.”</p>
<div class="lb-trans"><p>“我们与 C4 Therapeutics 的关系建立在十年的信任和共同的科学抱负之上。我们很高兴进入第三次合作，扩展我们长期的伙伴关系，以开创 DACs 这一新兴方式。”</p>
</div><p>In February 2026, Roche obtained acceptance from the US Food and Drug Administration for its new drug application submitted for the giredestrant oral therapy, along with everolimus, to treat breast cancer.</p>
<div class="lb-trans"><p>2026 年 2 月，罗氏 获得了美国食品药品监督管理局的接受 其提交的 giredestrant 口服治疗的新药申请，以及与依维莫司联合治疗乳腺癌的申请。</p>
</div>

罗氏和 C4 Therapeutics 将推进降解剂 - 抗体偶联物的研究